English Polski
Vol 14, No 4 (2008)
Review paper
Published online: 2008-12-19

open access

Page views 766
Article views/downloads 1797
Get Citation

Connect on Social Media

Connect on Social Media

Cardiovascular gene therapy: an application of HIF-1α gene

Maciej Małecki, Robert Proczka, Beata Chmiel, Agnieszka Kotlarz, Joanna Chorostowska-Wynimko
Acta Angiologica 2008;14(4):125-130.


Currently gene therapy is mostly focused on cancer treatment trials, cardiovascular and infectious diseases. Nowadays gene therapy for cardiovascular diseases is recognised thanks to successful clinical trials that have used mainly genes encoding proangiogenic citokines,eg vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), hepatic growth factor (HGF). Progress in gene therapy of cardiovascular diseases needs not only basic studies for “new” genes, but also needs good prepeared clinical trials. Hipoxia inducible factor (HIF-1) is a physiological regulator of processes related to angiogenesis with a potential therapeutic meaning. A protein encoded by HIF-1a activates groups of genes responsible for preservation of oxygen homeostasis, activation of angiogenesis, erythropoiesis, regulation of glucose metabolism. There are known preliminary studies describing that gene HIF-1a is used in therapy of cardiovascular diseases. Animal trials and first clinic tests point out that administration of gene preparation HIF-1a efficiently induces neovascularization in ischemic tissues . Further research will indicate if gene HIF will be useful in treating cardiovascular diseases and if yes then in what period of time we will get such a result.

Article available in PDF format

View PDF (Polish) Download PDF file